Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LTI 03 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RENEW
  • Sponsors Rein Therapeutics

Most Recent Events

  • 14 Aug 2026 According to a Rein Therapeutics media release, global phase 2 RENEW trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF) has surpassed 25% of its planned enrollment of approximately 120 patients and is progressing ahead of schedule. The company remains on track to report interim data in the second half of 2026. Company also expects the $57.5 million financing recently raised to fully fund the RENEW trial and support its operations through Q1 2028.
  • 21 Jul 2026 According to a Rein Therapeutics media release, Company is expecting initial topline data in 2H 2026.
  • 21 Jul 2026 According to a Rein Therapeutics media release, trial is now open and enrolling patients across all five planned countries, with Germany joining the United States, United Kingdom, Australia, and Poland.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top